Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL775644 | 0.81 | ALDH3A1 (0.34) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL799369 | 0.81 | ALDH3A1 (0.34) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL3210806 | 0.75 | ALDH3A1 (0.36) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL9001565 | 0.74 | ALDH1A1 (0.50) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL8333845 | 0.74 | — | — | |
| SCHEMBL774959 | 0.73 | ALDH3A1 (0.33) | ALDH3A1 | |
| SCHEMBL798900 | 0.73 | ALDH3A1 (0.33) | ALDH3A1 | |
| SCHEMBL7140484 | 0.72 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL6579911 | 0.72 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR | |
| SCHEMBL6577600 | 0.72 | ALDH1A1 (0.47) | ALDH3A1ALDH1A1TP53HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101177385-B | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG | 2011-06-15 | — | — | CN | disclosed |
| CN-100453529-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-101177385-A | Aryl sulfonic acid amides and analogues as well as its purpose in curing neural degeneration disease | BAYER AG (DE) | 2008-05-14 | — | — | CN | disclosed |
| CN-100371318-C | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2008-02-27 | — | — | CN | disclosed |
| CN-1754873-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2006-04-05 | — | — | CN | disclosed |
| US-6727279-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-27 | — | — | US | disclosed |
| US-6573278-B2 | For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20030073727-A1 | Novel arylsulphonamides and analogues | MITTENDORF JOACHIM (DE) | 2003-04-17 | — | — | US | disclosed |
| US-6545050-B1 | Prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity. | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-6469054-B1 | PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR FOR THE TREATMENT OF CEREBRAL APOPLEXY, CRANIOCEREBRAL TRAUMA, PAIN AND SPASTICITY | BAYER AKTIENGESELLSHAFT (DE) | 2002-10-22 | — | — | US | disclosed |
| US-20020072529-A1 | Arylsulfonamides and analogues | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-06-13 | — | — | US | disclosed |
| US-6262112-B1 | 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
| CN-1253545-A | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases | BAYER AG (DE) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073727-A1 | Novel arylsulphonamides and analogues | PRSS12, OPRL1, CTSH | ALDH3A1 2755/4885ALDH1A1 3823/4885TP53 4773/4885 |
| US-20020072529-A1 | Arylsulfonamides and analogues | ARSA, PRSS12, SNCA | ALDH3A1 1205/4885ALDH1A1 3020/4885TP53 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.